Product Information

Property	Description
Product Name	Anti-mouse/human RXRα Recombinant Monoclonal Antibody
Antibody ID	XM0007
Target Protein	Retinoic acid receptor RXR-alpha (RXRα / NR2B1)
UniProt Accession	P19793-1 human / P28700 mouse
Molecular Weight	Human: 50.8 kDa; Mouse: 51.2 kDa
Antibody Type	Recombinant monoclonal antibody
Host Species	Mouse
Recombinant Format	Full-length mouse IgG1
Isotype	Mouse IgG1
Species Reactivity	Mouse and human
Tested Applications	WB, ELISA
Recommended Dilution for WB	1:500–1:5000
Antigen	Recombinant epitope-Fc fusion protein
Epitope Sequence	SSPINGMGPPFSVISSPMGPH
Expression System	HEK293 cells
Purification	Protein G affinity chromatography
Conjugate	Unconjugated
Concentration	0.1 mg/mL
Storage Buffer	0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7
Storage Condition	Store at -20°C
Research Use	For research use only. Not for diagnostic or therapeutic applications.

Product Background

Retinoid X receptor alpha (RXRα, NR2B1) is a nuclear receptor that functions as a key transcriptional regulator through both homodimerization and heterodimerization with other nuclear receptors. RXRα is involved in retinoid signaling, lipid metabolism, glucose metabolism, inflammation, liver biology, and developmental regulation. Because RXRα acts as a central partner for multiple nuclear receptor pathways, it is widely studied in metabolism, pharmacology, toxicology, cancer biology, and transcriptional regulation.

Antibody Development

XM0007 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the RXRα epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.

The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.

Binding and specificity were evaluated by:

• ELISA using recombinant epitope-Fc fusion antigen
• Western blot using recombinant MBP-epitope fusion protein
• Western blot detection of overexpressed full-length human RXRα protein

Validation Data

ELISA Validation

ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.

Validation conditions:

• Well 1: Fc control protein
• Well 2: epitope-Fc fusion protein
• Detection substrate: TMB

Note: ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length RXRα protein binding in solution has not been tested by ELISA.

Western Blot Validation – Recombinant Fusion Protein

Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while minimal binding was observed against MBP control protein.

Validation conditions:

• Lane 1: MBP control protein
• Lane 2: MBP-epitope fusion protein
• Standard reducing Western blot

Western Blot Validation – Overexpressed Full-Length Human Protein

Western blot analysis confirmed recognition of overexpressed full-length human RXRα protein under reducing conditions.

Validation condition:

• Overexpressed human RXRα protein
• Standard reducing Western blot
• HRP-conjugated anti-mouse secondary antibody